During 2002-2010, nanotherapeutics matured from concept to translational potential, with a strong emphasis on targeted, systemically deliverable carriers. Research converged on designing functionalized nanoparticles capable of delivering diverse payloads—nucleic acids, chemotherapeutics, and antimicrobials—while enabling monitoring through imaging modalities. The field prioritized safety, pharmacokinetics, and scalable manufacturing, advancing from materials discovery toward clinically oriented frameworks. Influential Works: Key breakthroughs included demonstrating RNA interference in humans via targeted nanoparticle delivery, and in vivo tumor suppression through functionalized carbon nanotube carriers delivering paclitaxel. Gold nanoparticles emerged as multifunctional vectors enabling drug delivery, targeting, and imaging, while nanoparticle-based antibiotic delivery showed enhanced antimicrobial activity. These advances catalyzed translational nanomedicine programs and set the stage for multifunctional theranostic constructs.